US EditionPublished • loading... • Updated
Sentynl and PRG partner for Progerinin licence
Summary by Pharmaceutical-technology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Verdict Hospital+2 Reposted by 2 other sources
Sentynl and PRG partner for Progerinin licence
Sentynl Therapeutics has signed an agreement with PRG S&T to license Progerinin, an investigational molecule intended to treat HGPS.The post Sentynl and PRG partner for Progerinin licence appeared first on Hospital Management.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium